Deucravacitinib Found to Be Safe, Effective for Plaque Psoriasis

New data from a systematic review of randomized control trials indicated that moderate-to-severe psoriasis patients benefited from deucravacitinib as a first line treatment.

Related Keywords

California ,United States ,Campbellp Deucravacitinib ,Rileyk Spencer ,Tina Bhutani Wilson Liao ,Vidhatha Reddy ,Linkedin ,Psoriasis Area ,Severity Index ,Physician Global Assessment ,Dermatology Life Quality Index ,Fingernail Psoriasis ,Tina Bhutani ,Wilson Liao ,Clinical Utility ,Isevere Plaque Psoriasis ,Clinical Risk Management ,Moderate To Severe Plaque ,